HRP20090311T1 - 3- [(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino] -methyl}-1-methyl-1h -benzimidazol-5-car bonyl)-pyridine-2-yl-amino -propionic acid ethyl ester methane sulphonate and use thereof as a medicament - Google Patents

3- [(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino] -methyl}-1-methyl-1h -benzimidazol-5-car bonyl)-pyridine-2-yl-amino -propionic acid ethyl ester methane sulphonate and use thereof as a medicament

Info

Publication number: HRP20090311T1
Authority: HR; Croatia
Prior art keywords: methyl; hexyloxycarbonylamino; phenylamino; imino; amino
Prior art date: 2003-08-29

Application number

HR20090311T

Other languages

English (en)

Croatian (hr)

Inventor

Sobotta Rainer

Sieger Peter

Schmid Rolf

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-29

Filing date

2004-08-24

Publication date

2009-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34202202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090311(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-24 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2009-07-31 Publication of HRP20090311T1 publication Critical patent/HRP20090311T1/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

HR20090311T 2003-08-29 2004-08-24 3- [(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino] -methyl}-1-methyl-1h -benzimidazol-5-car bonyl)-pyridine-2-yl-amino -propionic acid ethyl ester methane sulphonate and use thereof as a medicament HRP20090311T1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10339862A DE10339862A1 (de)	2003-08-29	2003-08-29	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
PCT/EP2004/009432 WO2005028468A1 (fr)	2003-08-29	2004-08-24	Ethylester-methansulfonate d'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionique et son utilisation en tant que medicament

Publications (1)

Publication Number	Publication Date
HRP20090311T1 true HRP20090311T1 (en)	2009-07-31

Family

ID=34202202

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HR20090311T HRP20090311T1 (en)	2003-08-29	2004-08-24	3- [(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino] -methyl}-1-methyl-1h -benzimidazol-5-car bonyl)-pyridine-2-yl-amino -propionic acid ethyl ester methane sulphonate and use thereof as a medicament
HR20120028T HRP20120028T1 (hr)	2003-08-29	2012-01-10	3-[(2-{[4-heksiloksikarbonilamino-imino-metil)fenilamino]-metil}-1-metil-1-h-benzimidazol-5-karbonil)-piridin-2-il-amino]propionska kiselina-etilester-metansulfonat-hemihidrat i njegova primjena kao lijeka

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HR20120028T HRP20120028T1 (hr)	2003-08-29	2012-01-10	3-[(2-{[4-heksiloksikarbonilamino-imino-metil)fenilamino]-metil}-1-metil-1-h-benzimidazol-5-karbonil)-piridin-2-il-amino]propionska kiselina-etilester-metansulfonat-hemihidrat i njegova primjena kao lijeka

Country Status (35)

Country	Link
US (2)	US20050234104A1 (fr)
EP (2)	EP2060569B1 (fr)
JP (2)	JP5348842B2 (fr)
KR (1)	KR101331039B1 (fr)
CN (2)	CN102167695B (fr)
AR (2)	AR045520A1 (fr)
AT (2)	ATE430145T1 (fr)
AU (2)	AU2004274139B2 (fr)
BR (1)	BRPI0413849A (fr)
CA (2)	CA2749579C (fr)
CO (1)	CO5660265A2 (fr)
CY (2)	CY1109299T1 (fr)
DE (2)	DE10339862A1 (fr)
DK (2)	DK1660482T3 (fr)
EA (1)	EA009736B1 (fr)
EC (2)	ECSP066399A (fr)
ES (2)	ES2375896T3 (fr)
HR (2)	HRP20090311T1 (fr)
IL (1)	IL173885A (fr)
ME (1)	ME00340B (fr)
MX (1)	MXPA06001959A (fr)
MY (2)	MY145696A (fr)
NO (2)	NO334115B1 (fr)
NZ (2)	NZ545984A (fr)
PE (1)	PE20050348A1 (fr)
PL (2)	PL1660482T3 (fr)
PT (2)	PT2060569E (fr)
RS (2)	RS20060136A (fr)
SG (1)	SG145734A1 (fr)
SI (2)	SI2060569T1 (fr)
TW (2)	TWI375674B (fr)
UA (1)	UA85686C2 (fr)
UY (2)	UY28493A1 (fr)
WO (1)	WO2005028468A1 (fr)
ZA (1)	ZA200600518B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030181488A1 (en)	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en)	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) *	2003-08-16	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE102005020002A1 (de) *	2005-04-27	2006-11-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) *	2005-06-04	2006-12-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102006054005A1 (de) *	2006-11-16	2008-05-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
RU2010143901A (ru) *	2008-03-28	2012-05-10	Бёрингер Ингельхайм Интернациональ Гмбх (De)	Способ получения композиций дабигатрана для перорального введения
BRPI0915942A2 (pt) *	2008-07-14	2019-04-09	Boehringer Ingelheim International Gmbh	método para produção de compostos medicinais contendo dabigatrana
WO2010020600A1 (fr) *	2008-08-19	2010-02-25	Boehringer Ingelheim International Gmbh	Utilisation du dabigatran-étexilate pour le traitement de patients souffrant d’hypertension pulmonaire
JP2013510072A (ja)	2008-11-11	2013-03-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
US20120142703A1 (en)	2009-05-14	2012-06-07	Boehringer Ingelheim International Gmbh	New combination therapy in treatment of oncological and fibrotic diseases
HUP1000069A2 (en) *	2010-02-02	2012-05-02	Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag	New salts for the preparation of pharmaceutical composition
EP2542224B1 (fr) *	2010-03-01	2014-08-13	Ratiopharm GmbH	Composition pharmaceutique à voie orale contenant d'éxilate de dabigatrane
JP2013521318A (ja)	2010-03-08	2013-06-10	ラティオファルムゲー・エム・ベー・ハー	ダビガトランエテキシラートを含有する医薬組成物
EP2588090B2 (fr)	2010-07-01	2023-11-22	KRKA, tovarna zdravil, d.d., Novo mesto	Formes pharmaceutiques posologiques orales comprenant de l'étéxilate de dabigatran et ses sels pharmaceutiquement acceptables
WO2012027543A1 (fr)	2010-08-25	2012-03-01	Teva Pharmaceuticals Usa, Inc.	Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation
PL2603503T3 (pl)	2010-09-27	2015-12-31	Ratiopharm Gmbh	Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania
WO2012077136A2 (fr) *	2010-12-06	2012-06-14	Msn Laboratories Limited	Procédé de préparation de dérivés de benzimidazole et de leurs sels
HUP1100244A2 (hu)	2011-05-11	2012-11-28	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Gyógyszeripari intermedierek és eljárás elõállításukra
WO2012162492A1 (fr)	2011-05-24	2012-11-29	Teva Pharmaceutical Industries Ltd.	Noyau comprimé comprenant des acides organiques pour une composition pharmaceutique
CN103998024A (zh)	2011-12-22	2014-08-20	勃林格殷格翰国际有限公司	速释多单元微丸系统
WO2013111163A2 (fr)	2012-01-20	2013-08-01	Cadila Healthcare Limited	Procédé de préparation de dabigatran étéxilate mésylate et polymorphes d'intermédiaires de celui-ci
WO2013110567A1 (fr)	2012-01-24	2013-08-01	Boehringer Ingelheim International Gmbh	Nouvelle formulation de dabigatran à administration par voie orale
ES2895918T3 (es)	2012-02-21	2022-02-23	Towa Pharmaceutical Europe S L	Composiciones farmacéuticas orales de dabigatrán etexilato
EP2631234A1 (fr)	2012-02-23	2013-08-28	Esteve Química, S.A.	Formes solides de mesylate d'étexilate de dabigatran et leurs procédés de préparation
WO2013144971A1 (fr)	2012-03-27	2013-10-03	Cadila Healthcare Limited	Nouvelles formes solides de bisulfate et de mésylate d'étéxilate de dabigatran, et leurs procédés de préparation
EP2834224B1 (fr)	2012-04-02	2018-06-06	MSN Laboratories Limited	Procédés de préparation de dérivés de benzimidazole et de sels de ceux-ci
EP2872499A1 (fr) *	2012-07-16	2015-05-20	Interquim, S.A.	Procédé de préparation d'intermédiaires pour la synthèse d'étexilate de dabigatran, et formes cristallines de ces intermédiaires
EP2890692A1 (fr)	2012-08-31	2015-07-08	Ranbaxy Laboratories Limited	Procédé de préparation de la forme cristalline i du sel méthanesulfonate d'étéxilate de dabigatran
CN103664882A (zh) *	2012-09-20	2014-03-26	天津药物研究院	结晶变体形态的达比加群酯及其制备方法和用途
CN103864756B (zh) *	2012-12-11	2018-06-15	四川海思科制药有限公司	丁二磺酸达比加群酯及其制备方法和用途
EP2835370A1 (fr)	2013-08-08	2015-02-11	Medichem, S.A.	Nouveaux cristaux de dabigatran etexilate mésilate
CN104418840A (zh) *	2013-09-05	2015-03-18	天津汉瑞药业有限公司	甲磺酸达比加群酯无水化合物
IN2014MU00675A (fr)	2014-02-26	2015-10-23	Megafine Pharma P Ltd
CN104892574A (zh)	2014-03-04	2015-09-09	浙江海正药业股份有限公司	达比加群酯甲磺酸盐的晶型及其制备方法和用途
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals
CN108864049A (zh) *	2014-04-04	2018-11-23	江苏天士力帝益药业有限公司	达比加群酯甲磺酸盐新晶型及其制备方法
CN105461686A (zh) *	2014-08-25	2016-04-06	江苏豪森药业股份有限公司	制备高纯度甲磺酸达比加群酯晶型的方法
CN104825422B (zh) *	2014-09-29	2017-12-12	普济生物科技（台州）有限公司	含达比加群酯甲磺酸盐的药物组合物及其制备方法
EP3251672B1 (fr)	2014-12-31	2023-02-01	Shenzhen Pharmacin Co., Ltd.	Composition pharmaceutique contenant de dabigatran etexilate et procédé de préparation de cette dernière
CN104725360A (zh) *	2015-04-09	2015-06-24	重庆东得医药科技有限公司	一种甲磺酸达比加群酯ⅰ晶型的制备方法
WO2017111637A1 (fr)	2015-12-23	2017-06-29	Zaklady Farmaceutyczne Polpharma Sa	Composition pharmaceutique comprenant du dabigatran ou un sel pharmaceutiquement acceptable de celui-ci
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107778291A (zh) *	2016-08-31	2018-03-09	亚宝药业集团股份有限公司	一种甲磺酸达比加群酯晶型ⅱ的制备方法
EP3873916B8 (fr)	2018-10-29	2025-03-26	Shanghai Synergy Pharmaceutical Sciences, Ltd.	Nouveaux composés dipeptidiques et leurs utilisations
JP2020193184A (ja) *	2019-05-30	2020-12-03	ダイト株式会社	ダビガトランエテキシラートメタンスルホン酸塩の形態ｉの製造方法
EP3771465A1 (fr)	2019-08-01	2021-02-03	Zaklady Farmaceutyczne Polpharma SA	Composition pharmaceutique comprenant du dabigatran etexilate
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法
CN114380793B (zh) *	2020-10-20	2024-02-23	北京澳合药物研究院有限公司	一种甲磺酸达比加群酯晶型i的制备方法及其应用
US11446286B1 (en) *	2022-02-28	2022-09-20	King Faisal University	Treatment of fungal infections using dabigatran etexilate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087380A (en)	1949-11-24	2000-07-11	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4427468A (en) *	1976-01-16	1984-01-24	Her Majesty The Queen In Right Of Canada	Curable propellant binding systems with bonding agent combination
DE3000979A1 (de)	1980-01-12	1981-07-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de)	1981-06-19	1983-01-05	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale dipyridamolformen
DE3126703A1 (de)	1981-07-07	1983-01-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja)	1982-02-02	1983-08-10	Fujisawa Pharmaceut Co Ltd	医薬組成物
US4675405A (en)	1984-09-21	1987-06-23	American Home Products Corporation	Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (de)	1991-09-06	1993-03-11	Thomae Gmbh Dr K	Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5416099A (en)	1991-10-29	1995-05-16	Merck & Co., Inc.	Fibrinogen receptor antagonists
ZA928276B (en)	1991-10-31	1993-05-06	Daiichi Seiyaku Co	Aromatic amidine derivates and salts thereof.
EP0653935B1 (fr)	1992-08-05	2002-05-08	F.H. FAULDING & CO. LIMITED	Composition pharmaceutique sous forme de granules
JPH06340619A (ja)	1993-05-03	1994-12-13	Bristol Myers Squibb Co	グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
CA2134192A1 (fr)	1993-11-12	1995-05-13	Michael L. Denney	Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique
PE121699A1 (es) *	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en)	1997-04-29	2002-07-02	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19752843C2 (de)	1997-11-28	2003-01-09	Byk Gulden Lomberg Chem Fab	Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
DE10133786A1 (de)	2001-07-16	2003-02-06	Boehringer Ingelheim Pharma	Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
US6627646B2 (en) *	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs
DE10209982A1 (de)	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma	Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20030181488A1 (en)	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
KR101005716B1 (ko) *	2002-03-07	2011-01-05	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
DE10245624A1 (de) *	2002-09-30	2004-04-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
DE10235639A1 (de)	2002-08-02	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2004231306A1 (en)	2003-04-24	2004-11-04	Boehringer Ingelheim International Gmbh	Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
DE10337697A1 (de) *	2003-08-16	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
US20050107438A1 (en)	2003-09-03	2005-05-19	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
EP1609784A1 (fr)	2004-06-25	2005-12-28	Boehringer Ingelheim Pharma GmbH & Co.KG	Procédé pour la préparation de 4-(benzimidazolylméthylamino)-benzamidines
US20060222640A1 (en)	2005-03-29	2006-10-05	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de)	2005-04-27	2006-11-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de)	2005-06-04	2006-12-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de)	2005-12-21	2007-06-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de)	2005-12-21	2007-06-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen

2003
- 2003-08-29 DE DE10339862A patent/DE10339862A1/de not_active Withdrawn
2004
- 2004-08-13 US US10/918,017 patent/US20050234104A1/en not_active Abandoned
- 2004-08-24 CA CA2749579A patent/CA2749579C/fr not_active Expired - Lifetime
- 2004-08-24 ES ES09153155T patent/ES2375896T3/es not_active Expired - Lifetime
- 2004-08-24 UA UAA200603253A patent/UA85686C2/ru unknown
- 2004-08-24 PL PL04764411T patent/PL1660482T3/pl unknown
- 2004-08-24 HR HR20090311T patent/HRP20090311T1/xx unknown
- 2004-08-24 SI SI200431794T patent/SI2060569T1/sl unknown
- 2004-08-24 WO PCT/EP2004/009432 patent/WO2005028468A1/fr not_active Ceased
- 2004-08-24 CN CN2011100536316A patent/CN102167695B/zh not_active Expired - Lifetime
- 2004-08-24 KR KR1020067003994A patent/KR101331039B1/ko not_active Expired - Lifetime
- 2004-08-24 AT AT04764411T patent/ATE430145T1/de active
- 2004-08-24 PT PT09153155T patent/PT2060569E/pt unknown
- 2004-08-24 EP EP09153155A patent/EP2060569B1/fr not_active Revoked
- 2004-08-24 NZ NZ545984A patent/NZ545984A/en not_active IP Right Cessation
- 2004-08-24 DK DK04764411T patent/DK1660482T3/da active
- 2004-08-24 AU AU2004274139A patent/AU2004274139B2/en not_active Expired
- 2004-08-24 PT PT04764411T patent/PT1660482E/pt unknown
- 2004-08-24 MX MXPA06001959A patent/MXPA06001959A/es active IP Right Grant
- 2004-08-24 CA CA2537054A patent/CA2537054C/fr not_active Expired - Lifetime
- 2004-08-24 EP EP04764411A patent/EP1660482B1/fr not_active Expired - Lifetime
- 2004-08-24 CN CN2004800249521A patent/CN1845917B/zh not_active Expired - Lifetime
- 2004-08-24 NZ NZ578586A patent/NZ578586A/en not_active IP Right Cessation
- 2004-08-24 ES ES04764411T patent/ES2326654T3/es not_active Expired - Lifetime
- 2004-08-24 EA EA200600381A patent/EA009736B1/ru not_active IP Right Cessation
- 2004-08-24 BR BRPI0413849-0A patent/BRPI0413849A/pt not_active Application Discontinuation
- 2004-08-24 DE DE502004009431T patent/DE502004009431D1/de not_active Expired - Lifetime
- 2004-08-24 SG SG200805933-9A patent/SG145734A1/en unknown
- 2004-08-24 RS YUP-2006/0136A patent/RS20060136A/sr unknown
- 2004-08-24 RS RS20060136A patent/RS53370B/sr unknown
- 2004-08-24 JP JP2006524316A patent/JP5348842B2/ja not_active Expired - Lifetime
- 2004-08-24 DK DK09153155.8T patent/DK2060569T3/da active
- 2004-08-24 ME MEP-2008-506A patent/ME00340B/fr unknown
- 2004-08-24 AT AT09153155T patent/ATE529420T1/de active
- 2004-08-24 PL PL09153155T patent/PL2060569T3/pl unknown
- 2004-08-24 SI SI200431177T patent/SI1660482T1/sl unknown
- 2004-08-26 MY MYPI20093734A patent/MY145696A/en unknown
- 2004-08-26 MY MYPI20043499A patent/MY145632A/en unknown
- 2004-08-27 TW TW093125929A patent/TWI375674B/zh not_active IP Right Cessation
- 2004-08-27 AR ARP040103089A patent/AR045520A1/es unknown
- 2004-08-27 UY UY28493A patent/UY28493A1/es not_active Application Discontinuation
- 2004-08-27 TW TW100125555A patent/TWI418553B/zh not_active IP Right Cessation
- 2004-08-27 PE PE2004000824A patent/PE20050348A1/es not_active Application Discontinuation
2006
- 2006-01-18 ZA ZA2006/00518A patent/ZA200600518B/en unknown
- 2006-02-23 IL IL173885A patent/IL173885A/en active IP Right Grant
- 2006-02-28 CO CO06019918A patent/CO5660265A2/es not_active Application Discontinuation
- 2006-03-01 EC EC2006006399A patent/ECSP066399A/es unknown
- 2006-03-28 NO NO20061420A patent/NO334115B1/no not_active IP Right Cessation
2008
- 2008-01-30 US US12/022,655 patent/US7932273B2/en not_active Expired - Lifetime
2009
- 2009-07-23 CY CY20091100788T patent/CY1109299T1/el unknown
- 2009-08-28 AR ARP090103316A patent/AR073225A2/es unknown
- 2009-12-18 UY UY0001032342A patent/UY32342A/es not_active Application Discontinuation
2010
- 2010-04-13 AU AU2010201457A patent/AU2010201457B2/en not_active Expired
2011
- 2011-05-09 JP JP2011104428A patent/JP5566332B2/ja not_active Expired - Lifetime
- 2011-11-21 EC EC2011006399A patent/ECSP11006399A/es unknown
2012
- 2012-01-10 HR HR20120028T patent/HRP20120028T1/hr unknown
- 2012-01-11 CY CY20121100024T patent/CY1112222T1/el unknown
2013
- 2013-06-05 NO NO20130778A patent/NO20130778L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
SI2060569T1 (sl)	2012-01-31
HK1157760A1 (en)	2012-07-06
NO334115B1 (no)	2013-12-16
DE10339862A1 (de)	2005-03-24
RS20060136A (sr)	2008-06-05
ES2375896T3 (es)	2012-03-07
KR20070031830A (ko)	2007-03-20
SI1660482T1 (sl)	2009-10-31
IL173885A0 (en)	2006-07-05
NO20130778L (no)	2006-03-28
JP5566332B2 (ja)	2014-08-06
CA2749579A1 (fr)	2005-03-31
JP2011178803A (ja)	2011-09-15
EA200600381A1 (ru)	2006-08-25
AU2010201457B2 (en)	2012-05-10
AU2010201457A1 (en)	2010-05-06
CN1845917B (zh)	2011-05-11
EP1660482B1 (fr)	2009-04-29
CO5660265A2 (es)	2006-07-31
NO20061420L (no)	2006-03-28
NZ578586A (en)	2011-01-28
ZA200600518B (en)	2006-12-27
SG145734A1 (en)	2008-09-29
CA2537054A1 (fr)	2005-03-31
CY1109299T1 (el)	2014-07-02
CA2537054C (fr)	2011-12-06
DK2060569T3 (da)	2012-01-23
HK1096682A1 (en)	2007-06-08
PL1660482T3 (pl)	2009-08-31
MXPA06001959A (es)	2006-05-17
TW201202217A (en)	2012-01-16
TW200512206A (en)	2005-04-01
MY145632A (en)	2012-03-15
ES2326654T3 (es)	2009-10-16
IL173885A (en)	2015-04-30
DE502004009431D1 (en)	2009-06-10
ECSP11006399A (es)	2011-12-30
MEP50608A (en)	2011-02-10
MY145696A (en)	2012-03-30
KR101331039B1 (ko)	2013-11-20
CN1845917A (zh)	2006-10-11
NZ545984A (en)	2009-08-28
TWI418553B (zh)	2013-12-11
AU2004274139A1 (en)	2005-03-31
EP1660482A1 (fr)	2006-05-31
BRPI0413849A (pt)	2006-10-24
AU2004274139B2 (en)	2010-05-13
CY1112222T1 (el)	2015-12-09
AR073225A2 (es)	2010-10-20
EA009736B1 (ru)	2008-02-28
CN102167695B (zh)	2013-06-19
PL2060569T3 (pl)	2012-03-30
US20050234104A1 (en)	2005-10-20
US7932273B2 (en)	2011-04-26
CN102167695A (zh)	2011-08-31
PT1660482E (pt)	2009-06-04
PE20050348A1 (es)	2005-06-15
JP2007504106A (ja)	2007-03-01
EP2060569A1 (fr)	2009-05-20
ATE529420T1 (de)	2011-11-15
UA85686C2 (ru)	2009-02-25
ATE430145T1 (de)	2009-05-15
CA2749579C (fr)	2013-04-16
AR045520A1 (es)	2005-11-02
DK1660482T3 (da)	2009-08-24
JP5348842B2 (ja)	2013-11-20
PT2060569E (pt)	2011-12-29
TWI375674B (en)	2012-11-01
US20080119523A1 (en)	2008-05-22
ME00340B (fr)	2011-05-10
UY32342A (es)	2011-07-29
ECSP066399A (es)	2006-09-18
EP2060569B1 (fr)	2011-10-19
WO2005028468A1 (fr)	2005-03-31
UY28493A1 (es)	2005-03-31
RS53370B (sr)	2014-10-31
HRP20120028T1 (hr)	2012-01-31

Publication	Publication Date	Title
HRP20090311T1 (en)	2009-07-31	3- [(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino] -methyl}-1-methyl-1h -benzimidazol-5-car bonyl)-pyridine-2-yl-amino -propionic acid ethyl ester methane sulphonate and use thereof as a medicament
HN2005000016A (es)	2009-06-01	Procedimiento de preparacion
TW200716610A (en)	2007-05-01	Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
IL181421A0 (en)	2007-07-04	2,4-di(aminophenyl) pyrimidines as plk inhibitors
WO2008096829A1 (fr)	2008-08-14	Composés tricycliques
CY2012031I1 (el)	2015-08-05	Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
AU2003259267A1 (en)	2004-02-25	Substituted aminopyrimidines as neurokinin antagonists
EP1640372A4 (fr)	2010-09-22	Compose d'acide 1,4-benzodioxane sulfonique et son utilisation comme matiere acceptrice d'electrons
TW200716107A (en)	2007-05-01	Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
TW200744588A (en)	2007-12-16	Pharmaceutical composition for external use
MY139475A (en)	2009-10-30	Process for the preparation of (1s)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, acid addition salts thereof and its use for the synthesis of ivabradine and for its pharmaceutically acceptable acid addition salts
WO2008153154A1 (fr)	2008-12-18	Composé cyclique, matériau de base pour résine photosensible et composition pour résine photosensible
ZA200608416B (en)	2008-11-26	Herbicidal composition
WO2008136385A1 (fr)	2008-11-13	Composé amide et son utilisation
ATE491008T1 (de)	2010-12-15	Stapelbares modul
MX2010001938A (es)	2010-03-11	Metodos para preparar compuestos basados en 4-fenil-6-(2,2,2-trifl uoro-1-feniletoxi)pirimidina.
IL178166A0 (en)	2006-12-31	1,3,4-oxadiazol-2-ones as ppar delta
MX274842B (es)	2010-03-30	Procedimiento para la produccion de sales de (4,5-dihidroisoxazol- 3-il)tiocarboxamidina.
WO2009063993A1 (fr)	2009-05-22	Dérivé de pyridine fusionné et son utilisation
WO2008001371A3 (fr)	2009-04-30	Contenu multimédia choisi par un utilisateur
MX2009003106A (es)	2009-04-06	Nueva modificacion cristalina de 4-(n-metil-2-cloro-5-piridilmetil amino)-2,5-dihidrofuran-2-ona.
선우덕	2008	Long-term sustainable development of long term care insurance scheme for the elderly
TH87447A (th)	2007-11-09	รูปแบบหลายรูปแบบของ 3-[(2-{[4-(เฮกซิลอกซิคาร์บอนิลอะมิโน-อิมิโน-เมธิล)-เฟนิลอะมิโน]-เมธิล}-1-เมธิล-1h-เบนซิมิดาโซล-5-คาร์บอนิล)-ไพริดิน-2-อิล-อะมิโน]-โพรพิโอนิก แอซิด เอธิล เอสเทอร์
ITMO20040122A1 (it)	2004-08-21	Metodo per la produzione di etichette di piconoscimento,ed etichette cosi' ottenibili
ITNO20050006A1 (it)	2006-10-28	Arma a riconoscimento automatico di identita' dell'utilizzatore